Oncopeptides AB
Nasdaq Stockholm · LEI 549300J9WWQ5CBYQ1M77· Fiscal year 2025
Staff cost per employee
Not disclosed
Employees
Not disclosed
Quick read
- Revenue grew 124.7% year over year.
- Operating loss of $22.1M in 2025.
Last 3 years
Revenue
Operating income
See the share price on Google Finance ↗
Investor metrics
2025
- Operating margin
- -315.9%
- Net margin
- -350.9%
- Equity ratio
- -43.5%